Viceconte, G.; Buonomo, A.R.; Esposito, N.; Cattaneo, L.; Somma, T.; Scirocco, M.M.; Mainolfi, C.G.; Gentile, I. Salvage Therapy with Rezafungin for Candida parapsilosis Spondylodiscitis: A Case Report from Expanded Access Program. Microorganisms2024, 12, 903.
Viceconte, G.; Buonomo, A.R.; Esposito, N.; Cattaneo, L.; Somma, T.; Scirocco, M.M.; Mainolfi, C.G.; Gentile, I. Salvage Therapy with Rezafungin for Candida parapsilosis Spondylodiscitis: A Case Report from Expanded Access Program. Microorganisms 2024, 12, 903.
Viceconte, G.; Buonomo, A.R.; Esposito, N.; Cattaneo, L.; Somma, T.; Scirocco, M.M.; Mainolfi, C.G.; Gentile, I. Salvage Therapy with Rezafungin for Candida parapsilosis Spondylodiscitis: A Case Report from Expanded Access Program. Microorganisms2024, 12, 903.
Viceconte, G.; Buonomo, A.R.; Esposito, N.; Cattaneo, L.; Somma, T.; Scirocco, M.M.; Mainolfi, C.G.; Gentile, I. Salvage Therapy with Rezafungin for Candida parapsilosis Spondylodiscitis: A Case Report from Expanded Access Program. Microorganisms 2024, 12, 903.
Abstract
Candida spondylodiscitis (CS) is a rare disease, for which therapeutic option are limited to fluconazole or echinocandins and the treatment should be administered up to 12 months. In case of reduced azole susceptibility, there is a scarcity of therapeutic options with adequate bone penetration and limited toxicity.
We report the first case of successful use of rezafungin for a spondylodiscitis due to Candida parapsilosis with reduced susceptibility to azoles.
The patient, affected by paraplegia and short bowel syndrome, was diagnosed with CS with culture on vertebral biopsy guided by a 18-FDG-PET/CT scan. He received rezafungin 200 mg weekly for 26 weeks, after 10 weeks of previous antifungal treatment. He had a full clinical, radiologic and biochemical response to the therapy with rezafungin, with no adverse effects.
Rezafungin is a promising therapy for Candida osteomyelitis, especially when first line therapies are ineffective or contraindicated.
Medicine and Pharmacology, Epidemiology and Infectious Diseases
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.